Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC3 | Q13489 | 6/20 | 0.33 |
| ▸ | XIAP | P98170 | 4/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | BIRC7 | Q96CA5 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL818763 | 1.00 | BIRC3 (0.33) | BIRC3XIAPBIRC2BIRC7DPP8 | |
| SCHEMBL15501198 | 0.92 | BIRC3 (0.40) | BIRC3XIAPBIRC2BIRC7TNF | |
| SCHEMBL15501146 | 0.92 | BIRC3 (0.40) | BIRC3XIAPBIRC2BIRC7TNF | |
| SCHEMBL12405725 | 0.92 | BIRC3 (0.40) | BIRC3XIAPBIRC2BIRC7TNF | |
| SCHEMBL16508926 | 0.87 | BIRC3 (0.37) | BIRC3XIAPBIRC2BIRC7TNF | |
| SCHEMBL819050 | 0.85 | BIRC3 (0.34) | BIRC3XIAPBIRC2BIRC7TNF | |
| SCHEMBL820543 | 0.85 | BIRC3 (0.34) | BIRC3XIAPBIRC2BIRC7TNF | |
| SCHEMBL820694 | 0.84 | HTR2A (0.37) | — | |
| SCHEMBL818210 | 0.81 | BRD3 (0.36) | — | |
| SCHEMBL820302 | 0.81 | BRD3 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2009094287-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICAL CORPORATION (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | BIRC3 6/4885XIAP 1/4885BIRC2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.